Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 50/2025 December 14, 2025
- GSK5764227: An Antibody-Drug Conjugate Targeting B7-H3 Enters Phase 1/2 Trial December 12, 2025
- MHB048C: A New PSMA-Targeted Therapy for Advanced Solid Tumors December 12, 2025
- Logic-gated DARPins, a Promising Advancement in Immune Therapy for Solid Tumors December 11, 2025
Kaempferol: A Potential Treatment for Emotional Stress-Aggravated Prostate Cancer Metastasis
/in Preclinical Research/by MaxProtac NP18: A New Hope for Prostate Cancer Treatment
/in Preclinical Research, PROTACs/by MaxAI designed cancer drug gets FDA approval for clinical trials
/in Artificial Intelligence, Not PCa related/by MaxThe Future of Cancer Treatment (pan-cancer): A 3-in-1 Antibody Design
/in Immunotherapy, Not PCa related, Preclinical Research/by MaxTruqap Shows Promise in Treating a Subtype of Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxRethinking the “Lower is Better” Approach to LDL-C: Examining the Relationship Between Low LDL-C and Prostate Cancer Risk in Non-Hypertensive Men
/in Observational, Retrospective studies/by MaxNodularin-R Enhances Abiraterone’s Effectiveness Against Castration-Resistant Prostate Cancer In Vivo
/in Preclinical Research/by MaxOlaparib’s Effectiveness Duration in Prostate Cancer Treatment
/in Post-hoc/by Max